Loading provider…
Loading provider…
Hematology & Oncology Physician in Orange, CA
NPI: 1316999550Primary Practice Location
PROVIDENCE ST. JOSEPH HOSPITAL
1100 W Stewart Dr, Orange, CA
Primary Employer
Providence Medical Foundation
psjhmedgroups.org
HQ Phone
Get MD Madhavi's Phone Numberphone_androidMobile
Get MD Madhavi's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
CA State Medical License
1993 - 2027

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Medical Oncology
University of Southern California/LAC+USC Medical Center
Fellowship • Hematology
1997 - 1998
Fellowship • Medical Oncology
1995 - 1997
Rangaraya Medical College NTR
Medical School
Until 1987
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 281 | 665 |
| 2 | 36415Insertion of needle into vein for collection of blood sample | 130 | 555 |
| 3 | 85025Complete blood cell count (red cells, white blood cell, platelets), automated test | 123 | 569 |
| 4 | 96372Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | 37 | 113 |
| 5 | 80053Blood test, comprehensive group of blood chemicals | 30 | 95 |
Authors: Edward Alexson
Journal: J Support Oncol
Pilot cross-over study to evaluate Regenecare topical gel in patients with epidermal growth factor receptor (HER1/EGFR) inhibitors-induced skin toxicity: The final analysis.
Authors: Wong S, Osann K, Lindgren A, Byun T, Mummaneni M
Publication Date: 2008-05
Morphological characteristics of the regurgitant rheumatic mitral valve.
Authors: David Kawanishi, Zehyani Bankwala
Journal: Can J Cardiol
Lead Sponsor: SWOG Cancer Research Network
Collaborators: National Cancer Institute (NCI), Novartis
Intervention / Treatment: PROCEDURE: assessment of therapy complications